Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: The impact of therapy with biologicals

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Popa, Calin D ^a   Arts, Elke ^a   Fransen, Jaap ^a   Van Riel, Piet L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; LIPID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ATHEROGENESIS; ATHEROGENIC INDEX; BIOLOGICAL THERAPY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK MANAGEMENT; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; INFLAMMATION;

EID: 84867828233     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/785946     Document Type: Review

References (52)

1. Gabriel S. E., Crowson C. S., Kremers H. M., Doran M. F., Turesson C., O'Fallon W. M., Matteson E. L., Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis & Rheumatism 2003 48 1 54 58 2-s2.0-0037235944 10.1002/art.10705 (Pubitemid 36091647)
2. Pincus T., Sokka T., Wolfe F., Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis & Rheumatism 2001 44 6 1234 1236 (Pubitemid 32537519)
3. del Rincón I., Williams K., Stern M. P., Freeman G. L., Escalante A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis & Rheumatism 2001 44 12 2737 2745 (Pubitemid 34016192)
4. Ross R., Atherosclerosisan inflammatory disease. The New England Journal of Medicine 1999 340 2 115 126 2-s2.0-0033552883 10.1056/NEJM199901143400207 (Pubitemid 29054847)
5. Sattar N., McCarey D. W., Capell H., McInnes I. B., Explaining how high-grade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003 108 24 2957 2963 2-s2.0-0346365086 10.1161/01.CIR.0000099844.31524.05 (Pubitemid 37553561)
6. Van Doornum S., McColl G., Wicks I. P., Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis & Rheumatism 2002 46 4 862 873 2-s2.0-0036229685 10.1002/art.10089 (Pubitemid 34303796)
7. Smolen J. S., Landewé R., Breedveld F. C., Dougados M., Emery P., Gaujoux-Viala C., Gorter S., Knevel R., Nam J., Schoels M., Aletaha D., Buch M., Gossec L., Huizinga T., Bijlsma J. W. J. W., Burmester G., Combe B., Cutolo M., Gabay C., Gomez-Reino J., Kouloumas M., Kvien T. K., Martin-Mola E., McInnes I., Pavelka K., Van Riel P., Scholte M., Scott D. L., Sokka T., Valesini G., van Vollenhoven R., Winthrop K. L., Wong J., Zink A., Van Der Heijde D., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 2010 69 6 964 975 2-s2.0-77953696525 10.1136/ard.2009.126532
8. Toms T. E., Panoulas V. F., Douglas K. M. J., Griffiths H., Sattar N., Smith J. P., Symmons D. P. M., Nightingale P., Metsios G. S., Kitas G. D., Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Annals of the Rheumatic Diseases 2010 69 4 683 688 2-s2.0-77950325065 10.1136/ard.2009.115717
9. Peters M. J. L., Symmons D. P. M., McCarey D., Dijkmans B. A. C., Nicola P., Kvien T. K., McInnes I. B., Haentzschel H., Gonzalez-Gay M. A., Provan S., Semb A., Sidiropoulos P., Kitas G., Smulders Y. M., Soubrier M., Szekanecz Z., Sattar N., Nurmohamed M. T., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases 2010 69 2 325 331 2-s2.0-75749118959 10.1136/ard.2009.113696
10. McMahon M., Grossman J., FitzGerald J., Dahlin-Lee E., Wallace D. J., Thong B. Y., Badsha H., Kalunian K., Charles C., Navab M., Fogelman A. M., Hahn B. H., Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis & Rheumatism 2006 54 8 2541 2549 2-s2.0-33746977703 10.1002/art.21976 (Pubitemid 44205015)
11. Popa C., van Tits L. J. H., Barrera P., Lemmers H. L. M., Van Den Hoogen F. H. J., Van Riel P. L. C. M., Radstake T. R. D. J., Netea M. G., Roest M., Stalenhoef A. F. H., Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Annals of the Rheumatic Diseases 2009 68 6 868 872 2-s2.0-67449162091 10.1136/ard.2008.092171
12. Park Y. B., Lee S. K., Lee W. K., Suh C. H., Lee C. W., Lee C. H., Song C. H., Lee J., Lipid profiles in untreated patients with rheumatoid arthritis. Journal of Rheumatology 1999 26 8 1701 1704 2-s2.0-0008856783 (Pubitemid 29367308)
13. van Halm V. P., Nielen M. M. J., Nurmohamed M. T., Van Schaardenburg D., Reesink H. W., Voskuyl A. E., Twisk J. W. R., Van De Stadt R. J., De Koning M. H. M. T., Habibuw M. R., Van Der Horst-Bruinsma I. E., Dijkmans B. A. C., Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 2 184 188 2-s2.0-33846866318 10.1136/ard.2006.051672 (Pubitemid 46226052)
14. Ajeganova S., Fiskesund R., de Faire U., Hafstrom I., Frostegard J., Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritisa one year study. Clinical and Experimental Rheumatology 2011 29 6 942 950
15. Allanore Y., Kahan A., Sellam J., Ekindjian O. G., Borderie D., Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clinica Chimica Acta 2006 365 1-2 143 148 2-s2.0-32044432104 10.1016/j.cca.2005.08.010 (Pubitemid 43196430)
16. Curtis J. R., John A., Baser O., Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-TNF therapy. Arthritis Care and Research 2012 64 9 1251 1282
17. Dahlqvist S. R., Engstrand S., Berglin E., Johnson O., Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scandinavian Journal of Rheumatology 2006 35 2 107 111 2-s2.0-33646492303 10.1080/03009740500474578
18. Engvall I. L., Tengstrand B., Brismar K., Hafström I., Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Research and Therapy 2010 12 5, article R197 2-s2.0-77958030953 10.1186/ar3169
19. Jamnitski A., Visman I. M., Peters M. J. L., Dijkmans B. A. C., Voskuyl A. E., Nurmohamed M. T., Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Annals of the Rheumatic Diseases 2010 69 11 1929 1933 2-s2.0-78149475757 10.1136/ard.2009.127597
20. Kiortsis D. N., Mavridis A. K., Filippatos T. D., Vasakos S., Nikas S. N., Drosos A. A., Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. Journal of Rheumatology 2006 33 5 921 923 2-s2.0-33646445868
21. Kume K., Amano K., Yamada S., Hatta K., Ohta H., Kuwaba N., Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. The Journal of Rheumatology 2011 38 10 2169 2171
22. Nishida K., Okada Y., Nawata M., Saito K., Tanaka Y., Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocrine Journal 2008 55 1 213 216 2-s2.0-42049116079 10.1507/endocrj.K07E-043 (Pubitemid 351520200)
23. Peters M. J. L., Vis M., van Halm V. P., Wolbink G. J., Voskuyl A. E., Lems W. F., Dijkmans B. A. C., Twisk J. W. R., De Koning M. H. M. T., Van De Stadt R. J., Nurmohamed M. T., Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 7 958 961 2-s2.0-34347219723 10.1136/ard.2006.059691 (Pubitemid 46999801)
24. Popa C., Netea M. G., Radstake T., Van Der Meer J. W. M., Stalenhoef A. F. H., Van Riel P. L. C. M., Barerra P., Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases 2005 64 2 303 305 2-s2.0-13244252637 10.1136/ard.2004.023119 (Pubitemid 40193632)
25. Popa C., van den Hoogen F. H. J., Radstake T. R. D. J., Netea M. G., Eijsbouts A. E., Den Heijer M., Van Der Meer J. W. M., Van Riel P. L. C. M., Stalenhoef A. F. H., Barrera P., Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 11 1503 1507 2-s2.0-34848912752 10.1136/ard.2006.066191 (Pubitemid 350032660)
26. Seriolo B., Paolino S., Sulli A., Fasciolo D., Cutolo M., Effects of anti-TNF- α treatment on lipid profile in patients with active rheumatoid arthritis. Annals of the New York Academy of Sciences 2006 1069 414 419 2-s2.0-33745614045 10.1196/annals.1351.039 (Pubitemid 43989884)
27. Seriolo B., Paolino S., Ferrone C., Cutolo M., Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clinical Rheumatology 2007 26 10 1799 1800 2-s2.0-38449102126 10.1007/s10067-007-0702-2
28. Soubrier M., Jouanel P., Mathieu S., Poujol D., Claus D., Dubost J. J., Ristori J. M., Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008 75 1 22 24 2-s2.0-37649012449 10.1016/j.jbspin.2007.04.014
29. Spanakis E., Sidiropoulos P., Papadakis J., Ganotakis E., Katsikas G., Karvounaris S., Bizaki A., Kritikos H., Boumpas D. T., Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. Journal of Rheumatology 2006 33 12 2440 2446 2-s2.0-33846034460 (Pubitemid 46067823)
30. Tam L. S., Tomlinson B., Chu T. T., Li T. K., Li E. K., Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clinical Rheumatology 2007 26 9 1495 1498 2-s2.0-34547631047 10.1007/s10067-007-0539-8 (Pubitemid 47201685)
31. Vis M., Nurmohamed M. T., Wolbink G., Voskuyl A. E., De Koning M. H. M. T., Van De Stadt R. J., Twisk J. W. R., Dijkmans B. A. C., Lems W. F., Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. Journal of Rheumatology 2005 32 2 252 255 2-s2.0-13444302254 (Pubitemid 40209122)
32. Wijbrandts C. A., Van Leuven S. I., Boom H. D., Gerlag D. M., Stroes E. G. S., Kastelein J. J. P., Tak P. P., Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases 2009 68 8 1316 1321 2-s2.0-67651207993 10.1136/ard.2007.086728
33. Emery P., Keystone E., Tony H. P., Cantagrel A., Van Vollenhoven R., Sanchez A., Alecock E., Lee J., Kremer J., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases 2008 67 11 1516 1523 2-s2.0-52149099504 10.1136/ard.2008.092932
34. Genovese M. C., McKay J. D., Nasonov E. L., Mysler E. F., Da Silva N. A., Alecock E., Woodworth T., Gomez-Reino J. J., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis & Rheumatism 2008 58 10 2968 2980 2-s2.0-54949150604 10.1002/art.23940
35. Jones G., Sebba A., Gu J., Lowenstein M. B., Calvo A., Gomez-Reino J. J., Siri D. A., Tomšič M., Alecock E., Woodworth T., Genovese M. C., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases 2010 69 1 88 96 2-s2.0-73449118587 10.1136/ard.2008.105197
36. Kawashiri S. Y., Kawakami A., Yamasaki S., Imazato T., Iwamoto N., Fujikawa K., Aramaki T., Tamai M., Nakamura H., Ida H., Origuchi T., Ueki Y., Eguchi K., Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatology International 2011 31 4 451 456 2-s2.0-79954438244 10.1007/s00296-009-1303-y
37. Maini R. N., Taylor P. C., Szechinski J., Pavelka K., Bröll J., Balint G., Emery P., Raemen F., Petersen J., Smolen J., Thomson D., Kishimoto T., Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis & Rheumatism 2006 54 9 2817 2829 2-s2.0-33749363027 10.1002/art.22033 (Pubitemid 44497760)
38. Schultz O., Oberhauser F., Saech J., Rubbert-Roth A., Hahn M., Krone W., Laudes M., Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases. PLoS ONE 2010 5 12 2-s2.0-78650781728 10.1371/journal.pone.0014328 e14328
39. Smolen J. S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., Woodworth T., Alten R., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. The Lancet 2008 371 9617 987 997 2-s2.0-40749114497 10.1016/S0140-6736(08)60453-5 (Pubitemid 351392039)
40. Gonzalez-Juanatey C., Llorca J., Vazquez-Rodriguez T. R., Diaz-Varela N., Garcia-Quiroga H., Gonzalez-Gay M. A., Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Care and Research 2008 59 12 1821 1824 2-s2.0-57149111317 10.1002/art.24308
41. Kerekes G., Soltész P., Dér H., Veres K., Szabó Z., Végvári A., Szegedi G., Shoenfeld Y., Szekanecz Z., Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clinical Rheumatology 2009 28 6 705 710 2-s2.0-67349230306 10.1007/s10067-009-1095-1
42. Mathieu S., Pereira B., Dubost J. J., Lusson J. R., Soubrier M., No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology 2012 51 6 1107 1111
43. Raterman H. G., Levels H., Voskuyl A. E., Lems W. F., Dijkmans B. A., Nurmohamed M. T., HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Annals of the Rheumatic Diseases. In press
44. Dixon W. G., Watson K. D., Lunt M., Hyrich K. L., Silman A. J., Symmons D. P. M., Maiden N., Price T., Hopkinson N., O'Reilly S., Hordon L., Griffiths I., Porter D., Capell H., Hassell A., Benitha R., Choy E., Walsh D., Emery P., Knight S., Bruce I., Taggart A., Scott D., Thompson P., McCrae F., Goodfellow R., Kitas G., Jubb R., Abernethy R., Sanders P., Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis & Rheumatism 2007 56 9 2905 2912 2-s2.0-34848898513 10.1002/art.22809 (Pubitemid 47502736)
45. Gonzalez-Juanatey C., Llorca J., Sanchez Andrade A., Garcia-Porrua C., Martin J., Gonzalez-Gay M. A., Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clinical and Experimental Rheumatology 2006 24 3 309 312 2-s2.0-33744792493 (Pubitemid 44151152)
46. Kontush A., Chapman M. J., Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Current Opinion in Lipidology 2010 21 4 312 318 2-s2.0-77954956885 10.1097/MOL.0b013e32833bcdc1
47. Khera A. V., Cuchel M., De La Llera-Moya M., Rodrigues A., Burke M. F., Jafri K., French B. C., Phillips J. A., Mucksavage M. L., Wilensky R. L., Mohler E. R., Rothblat G. H., Rader D. J., Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. The New England Journal of Medicine 2011 364 2 127 135 2-s2.0-78651379500
48. Stock J., Importance of HDL functionality to cardiovascular risk. Atherosclerosis 2011 218 1 19 20 2-s2.0-79960467779 10.1016/j.atherosclerosis. 2011.06.025
49. Ansell B. J., Fonarow G. C., Fogelman A. M., The paradox of dysfunctional high-density lipoprotein. Current Opinion in Lipidology 2007 18 4 427 434 2-s2.0-34447341178 10.1097/MOL.0b013e3282364a17 (Pubitemid 47051922)
50. Charles-Schoeman C., Khanna D., Furst D. E., McMahon M., Reddy S. T., Fogelman A. M., Paulus H. E., Park G. S., Gong T., Ansell B. J., Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. Journal of Rheumatology 2007 34 7 1459 1464 2-s2.0-34447514113 (Pubitemid 47067979)
51. Arts E., Fransen J., Lemmers H., High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Research and Therapy 2012 14 3, article R116
52. Symmons D. P. M., Gabriel S. E., Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nature Reviews Rheumatology 2011 7 7 399 408 2-s2.0-79960015053 10.1038/nrrheum.2011.75